Bernstein says Argenx CEO change vindicated by celiac trial
Bernstein analysts said positive midstage celiac-disease trial results for Argenx's FB102 vindicate the company's earlier CEO change, citing a research note.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.